Double-Drug attack on Tough-to-Treat blood cancer
NCT ID NCT05002816
Summary
This study is testing whether combining two existing multiple myeloma drugs—belantamab mafodotin and elotuzumab—is safe and more effective than using them separately. It's for patients whose cancer has returned or stopped responding after at least three prior treatments. Researchers hope this all-immune targeted combination will better control the disease in this hard-to-treat group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06512, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.